Pathways of tau fibrillization.
New methods for analyzing tau fibrillization have yielded insights into the biochemical transitions involved in the process. Here we review the parallels between the sequential progression of tau fibrillization observed macroscopically in Alzheimer's disease (AD) lesions and the pathway of tau aggregation observed in vitro with purified tau preparations. In addition, pharmacological agents for further dissection of fibrillization mechanism and lesion formation are discussed.
Kuret
Jeff
J
Center for Molecular Neurobiology, Department of Molecular and Cellular Biochemistry, Ohio St. University College of Medicine and Public Health, 1060 Carmack Rd., Columbus, OH 43210, USA. kuret.3@osu.edu
Chirita
Carmen N
CN
Congdon
Erin E
EE
Kannanayakal
Theresa
T
Li
Guibin
G
Necula
Mihaela
M
Yin
Haishan
H
Zhong
Qi
Q
D000544:Alzheimer Disease / Q000378:metabolism*; D016229:Amyloid beta-Peptides / Q000737:chemistry / Q000378:metabolism; D001923:Brain Chemistry; D066298:In Vitro Techniques; D008869:Microtubule-Associated Proteins / Q000235:genetics; D008954:Models, Biological; D009154:Mutation; D016874:Neurofibrillary Tangles / Q000378:metabolism*; D010766:Phosphorylation; D020033:Protein Isoforms; D011994:Recombinant Proteins; D016875:tau Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*
D016229:Amyloid beta-Peptides; C054369:MAPT protein, human; D008869:Microtubule-Associated Proteins; D020033:Protein Isoforms; D011994:Recombinant Proteins; D016875:tau Proteins